Bio News
Three U.S. biotech companies plan to raise a combined total of more than $500 million through initial public offerings. Braveheart Bio accounted for the largest share, issuing 18.7 million shares to raise approximately $274.5 million. Atovia and Bojinx also plan to raise $182.4 million and $67.8 million, respectively, to fund clinical development of their pipelines.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
